SCHEMBL3370275

SCHEMBL3370275

CCOC(=O)C(Cc1ccc(OCCc2nc(-c3ccc4c(c3)OCO4)sc2C)c(F)c1)OCC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 5/20 0.47
PPARA Q07869 4/20 0.47
KDM4E B2RXH2 3/20 0.39
HSD17B10 Q99714 2/20 0.39
TP53 P04637 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAPT P10636 2/20 0.38
ACHE P22303 2/20 0.37
ALDH1A1 P00352 3/20 0.36
HPGD P15428 2/20 0.36
SIRT2 Q8IXJ6 2/20 0.36
SIRT1 Q96EB6 2/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
SIRT3 Q9NTG7 1/20 0.36
NPC1 O15118 1/20 0.36
GAA P10253 1/20 0.36
RAB9A P51151 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3373084 0.94 PPARG (0.49) PPARGPPARA
SCHEMBL3369948 0.86 PPARG (0.46) PPARGPPARA
SCHEMBL3371005 0.86 PPARG (0.45) PPARGPPARA
SCHEMBL3374198 0.86 PPARG (0.45) PPARGPPARAMAPT
SCHEMBL3372779 0.85 PPARA (0.45) PPARGPPARAKDM4EMAPT
SCHEMBL3370714 0.85 PPARG (0.40) PPARGPPARAMAPT
SCHEMBL3374400 0.83 PPARG (0.48) PPARGPPARA
SCHEMBL3371935 0.82 PPARG (0.39) PPARGPPARAMAPT
SCHEMBL3370163 0.80 PPARG (0.53) PPARGPPARA
SCHEMBL3373906 0.80 MAPT (0.43) PPARGPPARAKDM4EHSD17B10TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1537091-B1 NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS HOFFMANN LA ROCHE (CH) 2010-10-06 EP disclosed
US-6809110-B2 NONINSULIN DEPENDENT DIABETES; SUCH AS 2-ETHOXY-3-(4-(2-(5-METHYL-2-PHENYL-THIAZOL-4-YL)-ETHOXY)-BENZO(B)THIOPHEN-7-YL)-PROPIONIC ACID HOFFMANN-LA ROCHE INC. 2004-10-26 US disclosed
US-20040110807-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2004-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110807-A1 Thiazole derivatives SLC5A1, GPR119, INSR PPARG 181/4885PPARA 287/4885KDM4E 3260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.